PubMed Health⌕ Search

Biomedical subjects

Andrew P Landstrom

Publications and source records attributed to Andrew P Landstrom.

3 recordsLinked to original sources

Genetic Determinants of Early Heart Failure in Hypoplastic Left Heart Syndrome: A Prospective NC-DEFINE Study.

BACKGROUND: Survivors of hypoplastic left heart syndrome (HLHS), the most severe form of congenital heart disease, are at high risk for heart failure (HF). HF in early life is a major contributor to mortality in this vulnerable population. However, reliable approaches to identify infants at highest risk for early HF are currently lacking. OBJECTIVES: The purpose of this study was to evaluate whether ultra-rare variants in cardiomyopathy-associated genes are associated with HF risk in HLHS. METHODS: Neonates with HLHS were prospectively enrolled within the first 21 days of life at Duke University Health System. Children and adults with HLHS who were older than 21 days were enrolled from Duke University Health System and the University of North Carolina into an ambispective cohort. External HLHS cohorts from Nationwide Children's Hospital and Vanderbilt University Medical Center were evaluated to assess for reproducibility across institutions. Participants underwent genome sequencing, and ultra-rare variants in dilated cardiomyopathy-associated genes (minor allele frequency &#x2264;0.01%) were evaluated. The primary outcome was HF, categorized as severe (ventricular assist device implantation, heart transplantation, or death) or medically managed (reduced systemic ventricular ejection fraction and/or HF diagnosis requiring initiation or escalation of HF therapy). Associations between variant status and HF risk were assessed using Cox regression. RESULTS: Among 35 neonates in the prospective cohort, 7 (20.0%) developed severe HF, 10 (28.6%) developed medically managed HF, and 18 (51.4%) remained HF free. The presence of a likely pathogenic/pathogenic variant was associated with a marked 9-fold increased risk of severe HF compared with genotype-negative individuals (P = 0.02). Most severe HF events occurred within the first month of life (67%). Similar associations between likely pathogenic/pathogenic variants and severe HF were observed in the Nationwide Children's Hospital and Vanderbilt University Medical Center cohorts (11- and 3-fold increased risk, respectively; all P < 0.05). Associations were attenuated in the ambispective cohort (all P > 0.05), which consisted of individuals significantly older than the prospective cohort (P < 0.0001). CONCLUSIONS: This study provides the first prospective evidence linking dilated cardiomyopathy-associated variants to early-onset HF in HLHS. These findings suggest that genetic variation may contribute to myocardial vulnerability in HLHS, highlighting the potential for genetic screening to enable early risk stratification and guide precision medicine approaches in this high-risk population.

Humans↗

Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.

The unique molecular characteristic of chronic myeloid leukemia (CML), the disease-causing ABL (9q34) to BCR (22q11) translocation, has provided an invaluable tool for disease diagnosis and monitoring of treatment response. The traditional standard in this regard is bone marrow karyotype, also known as conventional cytogenetics (CC), which reveals a shortened chromosome 22, the Philadelphia chromosome, t(9;22)(q34;q11). CC in CML has also been effectively used for monitoring the response to drug therapy. However, this particular laboratory test misses submicroscopic BCR/ABL translocations and is suboptimal for minimal residual disease (MRD) assessment. Both fluorescence in situ hybridization (FISH) and reverse-transcriptase polymerase chain reaction (RT-PCR) feature higher sensitivity in terms of both diagnosis and MRD assessment in CML, compared to CC. Another advantage of these alternative tests is their effective applicability to peripheral blood specimens. The current review highlights the practical literature with respect to the use of FISH for CML whereas the use of RT-PCR has been extensively covered in recent communications.

Humans↗

Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.

The molecular signature of BCR-ABL fusion in chronic myeloid leukemia (CML) provides a unique tool for diagnosis and monitoring of tumor burden during therapy. The gold standard in this regard is conventional bone marrow cytogenetics. Peripheral blood fluorescent in situ hybridization (FISH) offers the possibility of a less invasive, more practical alternative method in terms of both cost and turnaround time. In the present study, we examined 296 paired samples from 65 patients with CML and demonstrate a tight correlation, in quantifying BCR-ABL burden between bone marrow cytogenetics, bone marrow dual color, double fusion (D-FISH), and peripheral blood D-FISH (P < 0.0001 for each). Furthermore, we demonstrate that peripheral blood D-FISH can be used as a surrogate for cytogenetic studies in monitoring cytogenetic remission status.

Adult↗